{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:35:34Z","timestamp":1771864534325,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2013,10,5]],"date-time":"2013-10-05T00:00:00Z","timestamp":1380931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In primary biliary cirrhosis (<jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>), biochemical criteria at 1\u00a0year are considered surrogates of response to ursodeoxycholic acid (<jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content>). However, due to the slow natural history of <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>, evaluation at 1\u00a0year may be suboptimal to assess the therapeutic response, particularly in early disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To determine whether evaluation of biochemical criteria at 1 year is a reliable surrogate of <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content> response in early <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed the prospectively collected data of 215 patients (untreated = 129; <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content>\u2010treated = 86) with early <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content> (normal baseline bilirubin\/albumin) and a median follow\u2010up of 8\u00a0years (range: 1\u201329.1). The 1\u2010year attainment rates of the Barcelona, Paris\u2010I, Paris\u2010<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> and Toronto definitions, and their predictive relevance for a poor outcome (death, transplantation, complications of cirrhosis), were assessed either as a result of <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content> or no treatment. Independent associations with attaining each <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content> response definition were identified by multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Untreated patients displayed 1\u2010year biochemical features compatible with \u2018treatment response\u2019 at rates (Barcelona: 36.4%, Paris\u2010I: 66.7%, Toronto: 59.7%, Paris\u2010<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>: 40.3%) similar to those obtained under <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content>. Depending on the definition, baseline <jats:styled-content style=\"fixed-case\">ALP<\/jats:styled-content>\u22643x<jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 4.80\u201335.90), <jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>\u22642x<jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 5.63\u20139.34) and early histological stage (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 3.67\u20133.87) were the stronger predictors for attaining the criteria. <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content> treatment was associated with attaining Barcelona (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> = 2.16) and Paris\u2010<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> = 2.84), but not Paris\u2010I, and not Toronto definition when excluding late histological cases. Paris\u2010I criteria were significantly predictive of long\u2010term outcomes (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> = 2.83) in untreated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In early <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>, biochemical criteria at 1\u00a0year reflect severity of the disease rather than the therapeutic response to <jats:styled-content style=\"fixed-case\">UDCA<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12522","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T02:41:04Z","timestamp":1381545664000},"page":"1354-1364","source":"Crossref","is-referenced-by-count":30,"title":["Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29\u2010year cohort study"],"prefix":"10.1111","volume":"38","author":[{"given":"V.","family":"Papastergiou","sequence":"first","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Tsochatzis","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodriquez\u2010Peralvarez","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Thalassinos","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pieri","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Manousou","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Germani","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rigamonti","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Arvaniti","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Karatapanis","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Burroughs","sequence":"additional","affiliation":[{"name":"The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health Royal Free Hospital and UCL London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043898"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12435"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00596.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220311"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00465-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20240"},{"issue":"3","key":"e_1_2_7_11_1","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gong Y","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00699.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.01.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22428"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.029"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.216"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.031"},{"key":"e_1_2_7_20_1","first-page":"A12","article-title":"UDCA response criteria identify a sub\u2010group of PBC patients with an inherently good prognosis rather than a specific disease response","volume":"59","author":"Patanwala I","year":"2010","journal-title":"Gut"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780111307"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520510023215"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04215.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02318.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591576706001205"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280203"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100102"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.023937"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23637"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12522","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:58:03Z","timestamp":1696492683000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,5]]},"references-count":29,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/apt.12522"],"URL":"https:\/\/doi.org\/10.1111\/apt.12522","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,5]]}}}